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William R. Drobyski,1,2 Marcelo Pasquini,1,2 Kathy Kovatovic,1,2 Jeanne Palmer,1,2
J. Douglas Rizzo,1,2 Ayman Saad,1,2 Wael Saber,1,2 Parameswaran Hari1,2Corticosteroid refractory graft-versus-host disease (GVHD) is one of the major challenges in the manage-
ment of allogeneic stem cell transplant recipients. Although numerous agents have been employed to treat
this patient population, no standardized second-line therapy exists. In this study, we report our experience
with the administration of tocilizumab, an anti-interleukin 6 receptor antibody, in the treatment of steroid
refractory GVHD. Tocilizumab was administered to 8 patients with refractory acute (n 5 6) or chronic
GVHD (cGVHD) (n 5 2) once every 3 to 4 weeks. The majority of patients with acute GVHD (aGVHD)
had grade IV organ involvement of the skin or gastrointestinal tract, whereas both patients with cGVHD
had long-standing severe skin sclerosis at the time of treatment. There were no allergic or infusion-
related adverse events. Treatment was discontinued in one patient over concerns that tocilizumab may
have worsened preexisting hyperbilirubinemia. Several patients also had transient elevations in serum trans-
aminase values. Infections were the primary adverse events associated with tocilizumab administration. Four
patients (67%) with aGVHD had either partial or complete responses apparent within the first 56 days of
therapy. One patient with cGVHD had a significant response to therapy, whereas the second had stabilization
of disease that allowed for a modest reduction in immune suppressive medications. These results indicate
that tocilizumab has activity in the treatment of steroid refractory GVHD and warrants further investigation
as a therapeutic option for this disorder.
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Graft-versus-host disease (GVHD) is the major
complication associated with allogeneic hematopoietic
stem cell transplantation. For several decades, the initial
management of acute GVHD (aGVHD) has been the
administration of corticosteroids, and approximately
50% of patients will respond to this therapeutic inter-
vention [1,2]. For those patients who fail to respond to
steroids, a number of agents have been evaluated as
second-line therapy, but no consensus has emerged for
the treatment of these patients. Various modalities have
been employed to treat steroid refractory GVHD.
These agents have generally fallen intobroad categories,
including cytostatic agents (mycophenolic acid,
pentostatin) [3-5], immunomodulating agents (mTor1Bone Marrow Transplant Program; and 2Department
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biologic therapies (rituximab, alemtuzumab, infliximab,
denileukindifitox) [10-14]. In this second-line treatment
setting, response rates have generally been much lower
(ie, on the order of 20%-30%), indicating the need
for more effective therapies in this patient population.
A prominent characteristic of GVHD is the pres-
ence of a proinflammatory milieu that is attributable
to conditioning regimen-induced host tissue damage
as well as secretion of inflammatory cytokines by
alloactivated donor T cells and other immune cell
populations [15,16]. This has been the rationale
for the administration of agents that interfere with
inflammatory cytokine signaling for the therapy of
GVHD. Interleukin 6 (IL-6) is a pleiotrophic
cytokine that is produced by a variety of cell types
and is reportedly elevated in the serum of patients
with ongoing GVHD [17]. Moreover, polymorphisms
in recipient and donor genotypes that result in in-
creased IL-6 production have been associated with
an increase in GVHD severity [18,19]. Recent
studies in murine models of GVHD have shown that
treatment with an anti-IL-6R antibody significantly
reduces GVHD-associated mortality and pathological
damage [20,21]. Whether this approach has merit for
the treatment of patients with GVHD, however, has
not been examined.
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is a humanized anti-IL-6 receptor antibody that blocks
IL-6 signalingandhasbeenFDAapproved for the treat-
ment of severe active rheumatoid arthritis. It reportedly
has remission-inducing efficacy in patients withmoder-
ate to severe rheumatoid arthritis, systemic juvenile
idiopathic arthritis, and multicentric Castlemans’
disease [22-24]. A recent case report demonstrated
that administration of tocilizumab was effective at
significantly reducing the severity of GVHD in the
gastrointestinal (GI) tract as determined by a marked
reduction in the volume of diarrhea [25]. The purpose
of this study was therefore to evaluate the efficacy and
toxicity of tocilizumab in the treatment of a cohort of
patients with steroid refractory GVHD.PATIENTS, MATERIALS, AND METHODS
Patient Population
Eight patients were treated with off label use of to-
cilizumab at the discretion of their attending physi-
cians from July 2010 to April 2011. Patients were
deemed to be eligible for treatment if they had under-
gone allogeneic stem cell transplantation and devel-
oped steroid refractory, biopsy-proven GVHD,
which could be in any tissue site (ie, skin, gut, etc.). Pa-
tients were classified as having steroid-resistant
aGVHD if any of the following occurred: (1) no
change or progression in the stage of skin GVHD after
at least 1 week of 2 mg/kg per day or more of methyl-
prednisolone in conjunction with extracorporeal pho-
topheresis (ECP); (2) lack of response of visceral (liver,
GI) GVHD despite treatment with 2 mg/kg per day or
more of methylprednisolone for at least 72 hours; (3)
progression of visceral GVHD despite treatment
with 2 mg/kg per day or more of methylprednisolone
for at least 48 hours; or (4) visceral GVHD progressing
to stage 4 after 24 hours of 2 mg/kg per day or more of
methylprednisolone. Patients with protracted acute
GVHD who did not respond to a minimum of
0.5 mg/kg/day steroid therapy after 4 weeks were eligi-
ble. Finally, patients with classic chronic GVHD
(cGVHD) who did not respond within 4 weeks after
at least 0.5 mg/kg/day steroid therapy were also eligi-
ble. All patients provided written informed consent
for hematopoietic progenitor cell transplantation
under studies approved by the institutional review
board (IRB) at the Medical College of Wisconsin
(MCW). GVHD-related data were collected prospec-
tively on each patient. The MCW IRB approved this
retrospective analysis of tocilizumab therapy for ste-
roid refractory GVHD.
Treatment
Tocilizumab was administered intravenously at
a dose of 8 mg/kg once weekly every 3 to 4 weeks. Pa-tients with documented responses continued to receive
treatment on this schedule. Patients who had attained
a complete remission were dose reduced to 4 mg/kg as
long as they remained on other immune suppressive
medications. Tocilizumab was discontinued once pa-
tients were able to be taken off all other immune sup-
pressive medications and were free of GVHD for at
least 1 month. Patients who did not respond to tocili-
zumab or had progression of disease were discontinued
from therapy.GVHD and Toxicity Assessment
The extent of aGVHD in GVHD target organs
was graded according to the criteria enumerated in
Glucksberg et al. [26]. The diagnosis of cGVHD was
determined using the National Institutes of Health
consensus criteria [27]. Scoring of skin and mucosal
abnormalities in patients with cGVHD was based on
criteria detailed in the cGVHD response criteria work-
ing group report [28]. Toxicity was assessed using the
National Cancer Institute (NCI) Common Terminol-
ogy Criteria for Adverse Events (CTCAE) version 4.Infection Monitoring
Blood and tissue-directed cultures for bacterial and
fungal pathogens (ie, urine, sputum, etc.) were ob-
tained at the discretion of the treating physician
when clinically indicated. All patients had weekly cyto-
megalovirus (CMV) Nucleic Acid Amplified Test
(NAAT) testing in the blood as well as Epstein-Barr vi-
rus (EBV), human herpes virus 6 (HHV-6), and adeno-
virus testing by polymerase chain reaction (PCR) in
the blood at least every 2 weeks.Response Definitions
Complete response (CR) was defined as an Interna-
tional Bone Marrow Transplant Registry (IBMTR)
score of 0 for the GVHD grading in all evaluable or-
gans. For a response to be scored as CR at day 56 or
later, the participant must have been in CR on that
day and have had no additional therapy for an earlier
progression, partial response (PR), or no response
(NR). PR was defined as improvement in 1 or more or-
gans involvedwithGVHDsymptomswithout progres-
sion in others. For a response to be scored as PR at day
56 or later, the participantmust have been inPRon that
day and have had no intervening additional therapy for
an earlier progression, PR, or NR. Mixed response
(MR) was defined as improvement in 1 or more organs
with deterioration in another organ manifesting symp-
toms of GVHD or development of symptoms of
GVHD in a new organ. Progression was defined as de-
terioration in at least 1 organwithout any improvement
inothers.NRwasdefinedasprogressionwithneworgan
involvement or increased organ-specific symptoms
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least 7 days of study drug administration, or no response
(no reduction in any GVHD organ staging) after study
drug administration. Patients receiving new additional
secondary therapy (including the need to reescalate the
steroid dose to $2.5 mg/kg/day of prednisone [or
a methylprednisolone equivalent of 2 mg/kg/day])
were also classified as nonresponders.
Statistical Analysis
This study is a descriptive case series of 8 consecu-
tive patients treated with tocilizumab for steroid
refractory GVHD.Descriptive statistics with a median
and a range were used to summarize the number of in-
fusions. GVHD outcomes were described on an
individual patient level.RESULTS
Patient and Disease Characteristics
The patient characteristics are shown in Table 1.
For all patients, except 1, this was the initial allogeneic
stem cell transplant. Patient UPN 2272, who was
transplanted for chronic lymphocytic leukemia
(CLL), had failed his first nonmyeloablative transplant
with persistent disease and evidence of graft rejection,
and was then treated with a second myeloablative
transplant from the same unrelated donor. All patients
failed therapy with multiple other agents in addition to
steroids (Table 2). Organ involvement in patients with
acute GVHD consisted of lower GI tract disease in
5 patients (grade II in 1 and grade IV in 4) and skin
involvement in 1 patient (grade IV). Two patients
had classic cGVHD that was characterized by diffuse
sclerosis of the skin with joint contractures.
Toxicity and Adverse Events
A total of 31 infusions of tocilizumab were admin-
istered during the study period. The median number
of infusions was 5 per patient (range: 1-6 infusions),
and the median time of administration posttransplan-Table 1. Patient Characteristics
UPN Age/Sex Disease
CMV Serostatus
(Donor/Recipient) Type of Transplant
2031 41/M MM Neg/Neg Nonmyeloablative, matched
2090 55/M MM Neg/Pos Nonmyeloablative, matched
2200 53/M MM Neg/Neg Nonmyeloablative, matched
2272 52/M CLL Neg/Pos Myeloablative, matched unre
2292 52/M MM Neg/Pos Nonmyeloablative, matched
2496 42/F AML Neg/Neg Myeloablative, mismatched u
2502 67/F CLL Neg/Neg Nonmyeloablative, matched
2503 40/F AML Pos/Pos Myeloablative, mismatched u
MM indicates multiple myeloma; CLL, chronic lymphocytic leukemia; AML, acu
late mofetil; ATG, antithymocyte globulin.tation was 4 months (range: 1-33 months). There
was no infusion or allergic-related events. Two pa-
tients developed grade 2 elevations in serum transam-
inases at some time during the course of tocilizumab
infusions. Of 31 total infusions, 8 were associated
with elevated transaminase levels that were either
grade 1 or 2 in severity. One patient (UPN 2031)
had a preexisting grade 1 increase in serum aspartate
aminotransferase/alanine aminotransferase (ALT/
AST) values, but these remained unchanged during
all infusions. Tocilizumab was discontinued in 1 pa-
tient (UPN 2503) after receiving a single infusion of
this agent because of worsening of preexisting grade
1 hyperbilirubinemia. No other patients required dis-
continuation of this agent because of toxicity.
Infection Assessment
Five patients developed infections during treatment
with 13 total documented infections. Nine (69%) of
these infectious episodes were of bacterial origin and,
except for 1 attributable to Clostridium difficile colitis,
were because of bloodstream infections. Two patients
developed fungal bloodstream infections attributable
to Fusarium sp and Candida sp. Two other patients
had viral infections; 1 withCMVcolitis, which occurred
temporallywith grade 4GVHDof the gut, and a second
with hemorrhagic cystitis because of BK viruria. CMV
viremia was preexisting in 3 patients (UPN 2090, 2272,
and 2292) before tocilizumab administration, having
developed this condition 1 to 4 weeks before antibody
treatment. Two patients cleared viremia after starting
tocilizumab (4 months and 2 months, respectively).
The third patient died 9 days after initiation of treat-
ment with detectable CMV viremia without evidence
of CMV disease. No patient developed CMV viremia
after initiation of tocilizumab. None of these patients
had evidence of EBV, HHV-6, or adenovirus reactiva-
tion or disease while on therapy.
Response to Treatment with Tocilizumab
The median time from onset of GVHD to ad-
ministration of tocilizumab was 36 days (range:Conditioning Regimen Acute GVHD Prophylaxis
related TBI 200 cGy Tacrolimus, MMF
related TBI 200 cGy Tacrolimus, MMF
related TBI 200 cGy Tacrolimus, MMF
lated TBI 1200 cGy
Cyclophosphamide
Tacrolimus, MMF
unrelated Fludarabine, TBI 200 cGy Tacrolimus, MMF, rapamycin,
nrelated Busulfan, cyclophosphamide ATG, tacrolimus, methotrexate
unrelated Fludarabine, TBI 200 cGy Tacrolimus, MMF
nrelated Busulfan, cyclophosphamide ATG, tacrolimus, steroids
te myelogenous leukemia; TBI, total body irradiation; MMF, mycopheno-
Table 2. GVHD Characteristics
UPN
Onset of GVHD
(Day Post-BMT)
Overall Stage
of GVHD Organ Involvement (Stage)† GVHD Therapy before Tocilizumab‡
Tocilizumab
Administration
(Day Post-BMT)
2031 724* Classic chronic Skin sclerosis, joint contractures Steroids, photopheresis, gleevec, plaquinel 984
2090 142 IV Gut (IV)
Liver (III)
steroids, infliximab (4), campath (2),
MMF, budesonide, octreotide
184
2200 487* Classic chronic Skin sclerosis, joint contractures Steroids, photopheresis, infliximab, gleevec,
sirolimus, lidocaine, campath (10),
rituxan (4), MMF, PUVA, plaquinel
669
2272 26 IV Skin (IV) Steroids, photopheresis 39
2292 106 II Gut (II) Steroids, infliximab (4), budesonide, tacrolimus 235
2496 23 IV Skin (II)
Gut (IV)
Steroids, infliximab (2), budesonide 51
2502 52 IV Skin (II)
Gut (IV)
Steroids, infliximab (3) 82
2503 24 IV Skin (II)
Gut (IV)
Steroids, MMF 32
MMF indicates mycophenolate mofetil; BMT, bone marrow transplant; GVHD, graft-versus-host disease.
*Denotes onset of chronic GVHD in these 2 patients.
†Gut involvement in these patients was all lower tract disease.
‡Number in parentheses indicates total number of infusions given of infliximab, campath, or rituxan.
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tients (67%) with aGVHD (Table 3). Two of 6 pa-
tients died with grade 4 aGVHD of the lower
gastrointestinal tract. One patient had no demonstra-
ble response to tocilizumab, whereas the second died
9 days after the first dose of tocilizumab with active
GVHD and was deemed to be nonevaluable. Two pa-
tients had a complete response at day 56, whereas 2
others had partial responses. The complete responses
were characterized by complete resolution of diarrhea.
In the responding group of patients, immune suppres-
sive medications were reduced in all patients to varying
degrees (Table 3).
Two patients (UPN 2031 and 2200) who were
treated with tocilizumab had classic cGVHD, which
was manifested predominantly by sclerosis of the
skin that was long-standing and refractory to multipleTable 3. Clinical Outcomes and Immune Suppressive Therapy*
UPN Response (Day 56) Current Status Cause of Death Pre
2031 Stabilization of skin
sclerosis
Alive, d+1123 — Prednisone
rap
2090 NE Dead, d+195 GVHD NA
2200 PR Alive, d+752 — Prednisone
gleeve
2272 PR Dead, d+213 Infection SoluMedrol
2292‡ CR Alive, d+496 — SoluMedrol
tacro
2496 CR Alive, d+174 — SoluMedrol
2502 PR Alive, d+157 — SoluMedrol
tw
2503 NR Dead, d+85 GVHD NA
NE indicates not evaluable; CR, complete response; PR, partial response; NR,
*Immune suppressive therapy pre- and post-tocilizumab is shown for respond
†Post-tocilizumab therapy refers to the immune suppressive regimen that eac
‡Post-tocilizumab steroid dose in this patient was replacement therapy to preprior immune suppressive medications (Table 2). No
validated scoring system has been identified for the as-
sessment of patients with sclerotic skin changes during
cGVHD [29]. For that reason, we employed serial
measurements of joint mobility as a surrogate indica-
tor for skin sclerosis and also incorporated elements
of the NIH consensus criteria for other aspects of
skin GVHD [29]. One patient had stabilization of dis-
ease while taking tocilizumab. He had no alteration in
his joint range of motion when serially evaluated by
a physical therapist and no improvement noted on
a cGVHD assessment scale. The steroid dose, how-
ever, was modestly reduced (Table 3). The second pa-
tient (UPN 2200) had a significant response to
tocilizumab. The most severely affected area of skin
sclerosis and joint contractures were in the lower ex-
tremities for this patient. The clinical response in-Tocilizumab Therapy Post-Tocilizumab Therapy†
30 mg every day, gleevec,
amycin, photopheresis
Prednisone 20/10 every other day,
rapamycin, photopheresis, plaquenil
NA
10 mg every day, rapamycin,
c, lidocaine, photopheresis
every 2 weeks
Prednisone 10 mg every other day,
photopheresis every 6 weeks
65 mg twice a day, tacrolimus Prednisone 30 mg every day
10 mg every day,
limus, MMF, budesonide
Hydrocortisone 20/10 mg
every day, budesonide
50 mg every day,
MMF, budesonide
Prednisone 20 mg every day, budesonide
50 mg twice a day, MMF 1 g
ice a day, tacrolimus
SoluMedrol 30 mg every day, MMF 750 mg
twice a day, tacrolimus
NA
no response; NA, not applicable; GVHD, graft-versus-host disease.
ing patients only.
h patient was taking at the time of last contact.
vent adrenal insufficiency.
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provements in the range of motion in multiple joints,
primarily in hip extension, knee flexion and exten-
sion, and ankle dorsiflexion (Supplementary Table
1). Increased flexibility in his lower extremities al-
lowed for improved gait, which resulted in a signifi-
cant augmentation in ambulation distance.
Furthermore, there was improvement in overall
skin and mucosal scores as well as a substantial reduc-
tion in his overall level of immune suppression.DISCUSSION
In this report, we examined the efficacy of tocilizu-
mab, an IL-6 receptor antibody that blocks signaling
of IL-6, in the treatment of patients with steroid
refractory GVHD. We observed overall clinical re-
sponses in 5 of 8 patients treated with tocilizumab.
The majority of patients with aGVHD had overall
grade 4 disease, with the GI tract being the predomi-
nant target organ. The median time from onset of
GVHD to administration of tocilizumab was 29 days
in this group. Thus, most patients who had failed ste-
roids had persistent, severe GVHD for several weeks
before tocilizumab was added to the regimen. Tocili-
zumab also appeared to have some efficacy in the treat-
ment of skin sclerosis because of cGVHD. Both
patients treated with this agent had failed multiple
prior modalities and had significant functional
limitations because of concurrent joint contractures.
One patient had stabilization of disease, which was as-
sociated with a modest reduction in his steroid dose,
whereas the second patient had a more dramatic re-
sponse with objective improvement in joint mobility,
a reduction in the amount of skin involvement, and sub-
stantial decrease in immune suppressive medications.
The rationale for the administration of tocilizu-
mab derived from preclinical studies that had demon-
strated that blockade of IL-6 signaling attenuates the
severity of GVHD [20,21]. Protection from GVHD
was attributed to a recalibration of the effector and
regulatory arms of the immune system. This was
characterized by a reduction in proinflammatory
TH1 and TH17 cells with a commensurate increase
in the number of regulatory T cells [20]. In particular,
these preclinical studies demonstrated a role for IL-6
in mediating pathologic damage within the colon mi-
croenvironment as increased levels of IL-6 were also
detected within the colon microenvironment [29].
Furthermore, blockade of IL-6 signaling with an
anti-IL-6R antibody resulted in more profound pro-
tection in the colon relative to other GVHD target or-
gans, such as the liver and lung. Thus, the clinical
responses we observed in the gut in tocilizumab-
treated patients, coupled with a prior report [25],
support a role for IL-6 in the pathophysiology ofGI GVHD. Whether blockade of IL-6 signaling in
allogeneic transplant recipients is able to augment
reconstitution of regulatory T cells, as observed inmu-
rine studies, was not addressed in this study and will re-
quire further investigation.
The responsiveness of sclerotic skinmanifestations
in 1 patient treated with tocilizumabmay provide some
new insight into the pathophysiology of skin fibrosis
during GVHD. Recent studies from Hill and col-
leagues [30] have demonstrated that cGVHD
induced in mice after transplantation of granulocyte-
colony stimulating factor (G-CSF)-mobilized stem
cell grafts is associated with development of sclero-
derma in the skin. This was reportedly because of the
overproduction of IL-17. IL-6 reportedly plays a piv-
otal role in the differentiation of TH17 cells from naive
T cells. Naive T cells stimulated with anti-CD3 and
anti-CD28 antibodies in the presence of transforming
growth factor-beta (TGF-b) differentiate into induced
regulatory T cells, whereas exposure to IL-6 along
with TGF-b drives them to become TH17 cells capa-
ble of secreting IL-17 [31,32]. Thus, blockade of IL-
6 may serve to decrease differentiation of na€ıve T cells
into TH17 cells and thereby attenuate skin sclerosis.
Alternatively, reported effects of tocilizumab on the
memory B cell compartment [33] is another mecha-
nism by which this agent may have facilitated a re-
sponse, given the role that B cells play in cGVHD
[13]. Notably, anti-IL-6 therapy reportedly suppresses
procollagen production in fibroblasts from sclero-
derma patients [34]. A recent report has also demon-
strated alleviation of fibrotic skin changes in a small
group of patients with primary scleroderma treated
with tocilizumab [35]. Collectively, these data point
to a role for IL-6 in the fibrosis and sclerotic skin
changes that can occur as a consequence of cGVHD,
and suggest that blockade of IL-6 may represent
a novel treatment approach for this complication.
Adverse events associated with tocilizumab admin-
istration were consistent with those previously
reported for this agent [22,23,36,37] and those
typically observed in allogeneic transplant recipients
(eg, infections). There were elevations in serum
transaminases in several patients, but these tended to
be modest and did not increase with subsequent
infusions. One patient required a liver biopsy because
of hyperbilirubinemia, which worsened to grade
4 after initiation of tocilizumab. The biopsy showed
no evidence of GVHD or CMV hepatitis, with
only cholestasis noted on pathologic examination.
The cause of her hyperbilirubinemia remained
undetermined, and it was uncertain the extent to
which tocilizumab may have contributed to this
abnormality. Infections were the major concurrent
event observed in many of these patients. It was
difficult, however, to determine whether tocilizumab
may have predisposed patients to infectious
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received multiple modalities for their GVHD
treatment and were all still taking other immune
suppressive medications at the time of tocilizumab
administration. All patients who were seropositive for
CMV reactivated this virus posttransplantation.
However, 3 of these 4 patients had CMV viremia that
antedated tocilizumab administration. One died
within 10 days after tocilizumab was begun with
refractory GVHD. In the remaining 2 patients,
viremia persisted for several months despite
continuous anti-CMV therapy, but none developed
CMV disease and eventually viremia cleared in both
patients. The fourth patient developed CMV colitis
post-tocilizumab administration.The remaining infec-
tions that were observed in this cohort of patients were
either bacterial or fungal in origin.
The tocilizumab dose administered in this study
was based on prior experience derived from the use
of this agent in adult patients with rheumatoid arthritis
[22]. In that report, a dose of 8 mg/kg was found to be
superior to 4 mg/kg when assessed at 3 months. For
that reason, all patients were initially treated at that
dose, although responding patients who remained on
immune suppressive medications were dose reduced
to 4 mg/kg in an effort to minimize exposure to an-
other immunosuppressive agent. We also employed
an administration schedule that was derived from prior
clinical arthritis studies where tocilizumab was given
approximately every 4 weeks. Although we were able
to document clinical responses in patients with
steroid-refractory GVHD, we do not know if this is
the optimal schedule. Prior studies have shown that in-
travenous innunoglobulin has a much shorter half-life
in bone marrow transplant recipients when compared
with normal controls [38]. Thus, it is possible that
a more frequent administration schedule might be
more clinically efficacious. In that regard, a recent
study in patients with Crohn’s disease, where tocilizu-
mab administration showed remission-inducing activ-
ity, was given on an every 2 week basis [39]. Further
studies will be needed to define this question.
In summary, these results demonstrate that toci-
lizumab has activity in the treatment of steroid
refractory GVHD. The response observed in pa-
tients with lower GI tract involvement coupled
with preclinical studies showing protection from
GVHDwithin the colon microenvironment suggests
that blockade of IL-6 signaling may represent a novel
approach for the prevention and/or treatment of
GVHD within this tissue site. Additionally, tocilizu-
mab may also provide benefits in the therapy of skin
sclerosis that occurs as a consequence of cGVHD.
Tocilizumab was generally well tolerated, although
whether this therapy predisposes patients to oppor-
tunistic infections remains to be determined. We
conclude that further investigation of this agentin patients with both aGVHD and cGVHD is
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